Paroxysmal Nocturnal Hemoglobinuria Syndrome Market Revenue, Opportunity, Forecast and Value Chain H1 2017

Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

PUNE, MAHARASHTRA, INDIA, April 3, 2018 /EINPresswire.com/ — Paroxysmal Nocturnal Hemoglobinuria  

Overview

Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache and shortness of breath. The predisposing factors include age, obesity and hormone therapy. Treatment includes surgery, chemotherapy and radiation therapy.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/1248514-paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2017

Paroxysmal Nocturnal Hemoglobinuria Industry Major Outlook

The Pharmaceutical and Healthcare latest pipeline guide Paroxysmal Nocturnal Hemoglobinuria – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 13 and 1 respectively.

Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders). 
– The pipeline guide reviews pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
– Find and recognize significant and varied types of therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders). 
– Classify potential new clients or partners in the target demographic. 
– Develop tactical initiatives by understanding the focus areas of leading companies. 

Table of Contents 
List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Paroxysmal Nocturnal Hemoglobinuria – Overview 
Paroxysmal Nocturnal Hemoglobinuria – Therapeutics Development 
Pipeline Overview 
Pipeline by Companies 
Products under Development by Companies 
Paroxysmal Nocturnal Hemoglobinuria – Therapeutics Assessment 
Assessment by Target 
Assessment by Mechanism of Action 
Assessment by Route of Administration 
Assessment by Molecule Type 
Paroxysmal Nocturnal Hemoglobinuria – Companies Involved in Therapeutics Development 
Achillion Pharmaceuticals Inc 

 …Continued

 

 For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1248514-paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Therapeutic Landscape of Medical Device Accessories Pipeline 2023

Global Medical Device Accessories Drugs and Companies Review 2023

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — Introduction
The global medical device and accessories market is driven by an increasing prevalence of chronic diseases and the growing demand for technologically advanced medical devices. Additionally, improvement of surgical outcomes and rising aging population also influence the market growth.
On the basis of the types of devices, the global medical device and accessories market is segmented into cardiovascular application, coronary pressure monitors, catheters, therapeutic medical guide, dental implant, cochlear implant, the global nerve stimulator market, the global diabetes monitors market, and the global suture needles market. Furthermore, the cardiovascular application segment is sub-segmented into cardiac monitors, cardiac pacemakers, cardiac defibrillators, and others. The coronary pressure monitor segment is sub-segmented into sphygmomanometer, automated blood pressure monitor, BP transducers, ambulatory blood pressure monitor, and instruments and accessories. The catheter segment is further sub-segmented into cardiovascular catheters, specialty catheters, intravenous catheters, urinary catheters, neurological catheters. The therapeutic medical guidewire segment is sub-segmented into solid guidewire and wrapped guidewire. The nerve stimulator market is sub-segmented into deep brain stimulator, vagus nerve stimulator, and spinal cord stimulator. The cardiovascular device accounted for the largest market share in 2016 and is expected to grow at a CAGR of 7.24%.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3100633-global-medical-device-accessories-market-research-report-forecast-to-2023

Key Players
The leading market players in the global medical device and accessories market include Boston Scientific Corporation, Medtronic, Johnson & Johnson Services, Inc., Stryker Corporation, Koninklijke Philips N.V., General Electric Company, Siemens AG, and Danaher Corporation.
Study Objectives of the Medical Device & Accessories Market
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenues of market segments and sub-segments with respect to regional- and country-level markets
• To provide historical and forecast revenue of market segments based on type, product, application, end-user, and its sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape of the market.

Target Audience
• Medical Device Companies
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities
• Medical Research Laboratories
• Market Research and Consulting Service Providers
• Potential Investors

Key Finding
• The global medical device and accessories market accounted for USD 79,879 million in 2016.
• The coronary pressure monitors segment is the fastest growing segment, which is projected to grow at a CAGR of 6.65% during the forecast period, 2017 to 2023.
• The Americas region captured the largest market globally and is expected to be USD 47,887 million by 2023.
• Asia Pacific is the fastest growing region across the globe and is expected to grow at a CAGR of 7.12% during the forecast period.

Table of Content: Key Points
1 Report Prologue
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Factor Analysis
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3100633-global-medical-device-accessories-market-research-report-forecast-to-2023

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

IoT Managed Services Market 2018–By Identifying the Key Market Segments Poised for Strong Growth in Future

IoT Managed Services Industry Business & Investment Opportunity (2018 – 2022) Market Research Reports

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — Introduction
IoT managed services enable interoperability with connected devices for solving business problems pertaining to operations, technical support, innovation or other verticals. The emergence of new technologies like ZigBee, which work on inexpensive batteries provide comfort in the development of connected devices. Increasing momentum of managed cloud services is one major factor driving the growth of IoT managed services market. Growing inclination towards cost efficient managed services is further fueling the market growth.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3100634-global-iot-managed-services-market-research-report-global-forecast-2022

The ongoing deployment of LTE and technological advancements in various fields have boosted the number of connected devices. The trend of a high attraction towards connected devices is observed worldwide. Emergence of new applications and advancements in technology in the field of wireless communication and worldwide interoperability for microwave access are increasing the number of connected devices. The IoT managed services market is broadly segmented on the basis of various end users, such as IT & telecommunication, healthcare, retail, automotive & transportation, manufacturing, and others.
By service, network management service type is expected to hold the largest share of the global IoT managed services market. Network management services basically deal with the entire network chain of an organization. These services help in analyzing the amount of data being transferred over a network and automatically routes it in order to avoid congestion which can result in a network crash. Managed services help in building a smart, connected & secured enterprise without shifting the focus of the organization from their core business operations.
The global IoT managed services market is expected to grow approximately at USD 84.1 Billion by 2022, at an approx. CAGR of 24% between 2016 and 2022.

Key Players
The key players of IoT managed services market include Accenture Plc. (Ireland), Cisco System Inc. (U.S.), Google Inc. (U.S.), AT & T Inc. (U.S.), Qualcomm Inc. (U.S.), International Business Machines Corporation (IBM) (U.S.), Oracle Corporation (U.S.), Microsoft Corporation (U.S.), Hewlett Packard Enterprise (U.S.), Intel Security Group, and Apple Inc. (U.S.) among others.

• To provide a detailed analysis of the market structure along with a forecast of the various segments and sub-segments of the IoT managed services market
• To provide insights into factors affecting the market growth
• To analyze the IoT Managed Services market based on Porter’s five forces analysis
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World
• To provide country-level analysis of the market concerning the current market size and prospects
• To provide country-level analysis of the market segment by services, end-user and organization size
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments, such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the IoT managed services market

Target Audience
• Technology Investors
• Research/Consultancy Firms
• IoT Managed Services Manufacturers
• Managed Service Providers (MSPs)
• Cloud Service Providers (CSPs)
• IT service providers
• IoT Technology Vendors
• Network Management Service Providers
• Support & Maintenance Service Providers
• Infrastructure Service Providers
• Government Associations

Key Findings
• The global IoT managed services market is estimated to reach USD 84.1 billion by 2022.
• By service, network management sub-segment in IoT managed services market accounts for the largest market share and is growing at a 24.35% CAGR, during the forecast period.
• By end user, automotive & transport sub-segment holds the largest market share in 2016, growing at a 26.17% CAGR, during the forecast period.
• By organization size, large enterprises sub-segment holds the largest market share and is growing at a 25.34% CAGR, during the forecast period.
• Geographically, North America has been projected to hold the largest market share in global IoT managed services market, followed by Europe and Asia Pacific in the second and third positions, respectively.

Regional and Country Analysis of IoT Managed Services Market Estimation and Forecast
IoT managed services market has a positive growth in all the regions. The high penetration rate of the internet of things managed services and advancements in technology are responsible for driving the growth of the IoT managed services market. On the basis of region, the market has been segmented into North America, Europe, Asia Pacific and Rest of the World. North America is dominating the global IoT managed services market followed by Europe, which has the second largest market share due to increasing developments in the automotive sector whereas, Asia Pacific stands as the third largest.

Table of Content: Key Points
1 Market Dynamics
2 Global IoT Managed Services Market, By Services
3 Global IoT Managed Services Market, By End-Users
4 Global IoT Managed Services Market, By Organization Size
5 Regional Market Analysis
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3100634-global-iot-managed-services-market-research-report-global-forecast-2022

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Glomerulonephritis Syndrome Market Segmentation Detailed Study with Forecast during H1 2017-2022

Glomerulonephritis

Glomerulonephritis

PUNE, MAHARASHTRA, INDIA, April 3, 2018 /EINPresswire.com/ — Glomerulonephritis
Overview
Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1248512-glomerulonephritis-pipeline-review-h1-2017
Glomerulonephritis Industry Major Outlook
The Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
– The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glomerulonephritis – Overview
Glomerulonephritis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Glomerulonephritis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
…Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1248512-glomerulonephritis-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Artificial Blood and Plasma Market 2018 – Opportunity, Driving Trends and deep study.

Artificial Blood and Plasma Market 2018 Global Industry Analysis, Opportunities and Forecast To 2027

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — Summary
The human body contains a vital fluid called blood, which delivers oxygen and nutrients to the body cells and carries waste products away from the cells in a gas exchange process. The artificial bloods being developed are intended to satisfy some of the functions of biological blood, particularly in humans. The objective of first-generation oxygen-carrying blood substitutes is solely to imitate blood’s oxygen transport function. Intense research is going on with more functional artificial blood, which could hypothetically emulate additional components and functions of human blood. Currently, two fundamental approaches to artificial blood are being taken: perfluorocarbons and hemoglobin-based oxygen carriers. These artificial blood products could increase survival of patients, especially during surgery when blood loss is high.

Blood shortages and the lack of appropriate substitutes have resulted in numerous preventable deaths. In the future, blood shortfalls may be even more severe, as current shortage projections do not take into account the more intense need for blood in cases of mass civilian casualties, such as common calamities, terrorist assaults and wars.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3096322-artificial-blood-and-plasma-global-markets-to-2027

Report Scope:
The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products. The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.

The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included. Excluded from consideration are product physical and chemical properties, detailed and unpublished clinical/lab results on the products, and detailed methodology/techniques used for product production.

Report Includes:
– 144 tables
– An overview of global market for artificial blood plasma
– Analyses of global market trends, with projections of compound annual growth rates (CAGRs) through 2027
– Identification of growth-driving factors influencing the artificial blood plasma market, as well as opportunities, restraints, and technological developments
– Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.Report Scope:

The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products. The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.

The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included. Excluded from consideration are product physical and chemical properties, detailed and unpublished clinical/lab results on the products, and detailed methodology/techniques used for product production.

Report Includes:
– 144 tables
– An overview of global market for artificial blood plasma
– Analyses of global market trends, with projections of compound annual growth rates (CAGRs) through 2027
– Identification of growth-driving factors influencing the artificial blood plasma market, as well as opportunities, restraints, and technological developments
– Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.Alliance Pharmaceutical Corp
BAXTER HEALTHCARE CORP.
BIOPURE CORP.
FLUORO2 THERAPEUTICS,INC.
Hemobiotech, Inc.
Northfield Laboratories Inc.
Nuvox Pharma Llc.
Prolong Pharmaceuticals, Llc
Sangart, Inc.
Sanguine Biosciences
Tenax Therapeutics Inc.
Therapure Biopharma Inc.

Table of Content: Key Points
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Contribution of the Study and Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts' Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Introduction
Chapter 3 Market Overview
Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3096322-artificial-blood-and-plasma-global-markets-to-2027

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Biosimilars Market Research Report 2018 Analysis and Forecast to 2022

Biosimilars Global Market 2018: Key Players BIOCAD, LG, Cinnagen, Allergan

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — Summary
Biosimilars, also known as “follow-on biologics,” “similar biologics,” “biogenerics,” etc. are the generic versions of the biologic drugs. They are important biotherapeutic drugs that are used for the treatment of several serious and debilitating diseases. Most of the innovator biologics are billion-dollar drugs and have a sizeable share of the biopharmaceuticals market. The high cost associated with the biologics has created a situation of limited access for millions of patients around the globe, in particular, the emerging countries. The patent expirations of the blockbuster drugs have led to a growing interest in the development of biosimilars. Biosimilars have the potential to allow wide and affordable access of the drugs due to their lower cost.

It has been noted by industry analysts that, compared to an originator biologic, a biosimilar takes 60% less time to reach the market, with development costs only 15% to 20% of those of the biologics. Their prices being 20% to 30% cheaper than the original drugs, the biosimilars offer increased opportunity for patients, healthcare providers, and manufacturing companies alike.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3096320-biosimilars-global-markets

The cost-effectiveness of biosimilars, soon-to-market approval option, and the billions of dollars’ worth market of term-end innovator biologics is luring many small and big pharmaceutical companies to capitalize in this market. The biosimilar industry comprises of pharmaceutical companies that range from clinical-stage companies to small-pharma companies with limited capabilities, as well as bigger pharmaceutical giants with established markets. Though the domestic markets are more flourished in the current situation, collaborations and partnerships proving as popular strategies to gain market share globally.

Europe has set an example for other countries by establishing a well-worked framework for the approval of biosimilars. The U.S., with the enactment if the Affordable Care Act in 2010, also entered this market in 2015. Emerging markets, including countries in Asia, Latin America, Russia, etc., have several biosimilar products in the market since the early 2000s. The products in these countries were, however, considered inferior in quality as these countries did not have any regulatory guidelines for biosimilar approvals. Lack of any patent regulation also favored these countries and allowed the market of biosimilars to flourish in the emerging markets. Governments of many countries have now adopted the biosimilar guidelines, encouraging the growth of global biosimilars market. Although, the acceptance of biosimilar drugs has been slow in the U.S., the recent approvals by the Food and Drug Administration (FDA) amounting to eight approvals in 2016 and 2017 in contrast to a single approval in 2015, show that the trend towards biosimilars in the developed world is gaining traction.

The global biosimilars market is driven primarily by the blockbuster products and the related research pipeline. Currently, there is only a limited number of biosimilars in the market, restricted to the categories of growth hormones, growth factors, monoclonal antibodies, fusion proteins, interferons, and low-molecular-weight heparins (LMWHs). During the examined period of this report, many more biosimilars, particularly in the categories of monoclonal antibodies indicated for the treatment of cancer, various autoimmune diseases, infectious diseases, and others are expected to be launched due to their impending patent expirations in the U.S. and Europe. There are at least 43 potential biosimilars candidates that are in late-stage clinical trials. The market of biosimilars is also encouraged by the successful joint ventures, collaborations and partnerships, and various licensing arrangements that are helping to boost the technical expertise, intellectual know-how, and market access for the partnering companies. An increase in the aging population, rising incidences of various diseases, and increasing pressure to cut healthcare expenditures are the growth drivers for the biosimilars market.Report Scope:

Biosimilars are replicas of the innovator biopharmaceuticals. They offer the advantage of being less expensive as compared to their expensive counterparts. The structural and manufacturing complexities associated with their development have led to extensive approval guidelines and regulations by the federal agencies. This report examines the biosimilar drugs in detail and provides an updated overview including its applications in various arenas of disease sectors. The importance of analytical technologies in the biosimilar manufacturing led BCC Research to focus specifically on the current and emerging trends in biosimilar manufacturing and analytical testing.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the biosimilar drugs industry. The company profiles highlight the bosimilar pipelines of relevant companies. Some of the major players of the market include Pfizer Inc., Sandoz International GmbH, Biocon Ltd., Dr Reddy’s Laboratories Ltd., Amgen Inc., Teva Pharmaceuticals Inc., Celltrion Inc., Samsung Bioepis, and others.
The report has also dealt with biobetters, their approval mechanisms and importance in the industry. (Biobetters are described as new molecular entities that are related to existing biologics by target or action, but they are deliberately altered to improve disposition, safety, efficacy, or manufacturing attributes.)
Excluded from this report are the generics of small-molecule drugs, and the biologics per se. The different requirements for approval and bioequivalence between generics and biosimilars puts them in an entirely different regime. The diagnostic methods for monitoring disease progression are also outside the scope of this report.

Report Includes:
– An overview of the global market for biosimilars
– Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
– A look at biosimilar product classes in various regions worldwide, as well as the worldwide pipeline for biosimilars
– Detailed analysis of the emerging framework in regulated markets, as well as comparisons of biosimilar guidelines in Europe, the U.S., Japan, Canada, as well the guidelines developed by the – World Health Organization
– Technology trends and patent analyses
– Comprehensive company profiles of key players in the market, including Allergan Plc., Bioton S.A., Cinnagen, Emcure Pharmaceuticals Ltd., LG Life Sciences, Neuclone and Pfizer Inc.3S BIO INC.
ALLERGAN PLC.
AMGEN INC.
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO. LTD.
APOTEX INC.
AVESTHAGEN LTD.
BHARAT SERUMS AND VACCINES LTD.
BIOCAD
BIOCON LTD.
BIOSIDUS S.A.
BIOTON S. A.
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3096320-biosimilars-global-markets

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Transmembrane Prolyl 4 Hydroxylase – Disease Assessment and Therapeutics Analysis Forecasts to 2024

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Transmembrane Prolyl 4 Hydroxylase – Pipeline Review, H1 2018”

Transmembrane Prolyl 4 Hydroxylase

Overview                

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Prolyl 4 hydroxylases (P4H) are iron- and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation.

This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3079825-transmembrane-prolyl-4-hydroxylase-hypoxia-inducible-factor-prolyl

 

Major Key Players:

Bayer AG

FibroGen Inc

GlaxoSmithKline Plc

Japan Tobacco Inc

Sigmoid Pharma Ltd

Transmembrane Prolyl 4 Hydroxylase Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Transmembrane Prolyl 4 Hydroxylase    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Transmembrane Prolyl 4 Hydroxylase   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 2 respectively.

Transmembrane Prolyl 4 Hydroxylase pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Transmembrane Prolyl 4 Hydroxylase – Competitive Analysis

Key players are making innovative developments in Transmembrane Prolyl 4 Hydroxylase industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Transmembrane Prolyl 4 Hydroxylase.

The pipeline guide reviews pipeline therapeutics for Transmembrane Prolyl 4 Hydroxylase by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Transmembrane Prolyl 4 Hydroxylase therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Transmembrane Prolyl 4 Hydroxylase therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Transmembrane Prolyl 4 Hydroxylase.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3079825-transmembrane-prolyl-4-hydroxylase-hypoxia-inducible-factor-prolyl

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Wood Preservation Market Analysis 2018 (By Segment, Key Players and Applications) and Forecasts To 2022

Wood Preservation Market 2018 Global Analysis, Opportunities and Forecast to 2022

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — Summary
Global wood preservation market growth outlook is positive with significant growth potential for ecofriendly wood products, thereby driving the demand for the wood preservation industry. Emerging market growth, low interest rate environment, rapid urbanization, rising populations, rapid growth in manufacturing and construction industries is driving demand for the wood preservation industry. At the same time, there is mounting pressure on wood preservation companies to procure wood from sustainable forests and reduce operational costs.

The market for wood preservation reached a value of nearly $REDACTED billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to nearly $REDACTED billion by 2022.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3096323-wood-preservation-global-markets-to-2022

The market for wood preservation is concentrated with a few large players dominating the market. Major players in the market are Stella-Jones Inc., West Fraser Timber Co. Ltd, UPM-Kymmene Corporation, Universal Forest Products, Inc., and Metsa Group. Pressure Treatment accounted for the largest share of the market for wood preservation in 2017 at REDACTED%. The highest growth is projected tocome from pressure treatment which is forecasted to grow at a CAGR of REDACTED%.. Asia pacific is the largest market for wood preservation, accounting for REDACTED% of the global market. Itwas followed by North America and Western Europe. Going forward, Eastern Europe is expected towitness the fastest growth in the wood preservation market, estimated at grow at a CAGR of REDACTED%, followed by Africa, which is expected to grow at a CAGR of REDACTED%. China is the largest market in terms of value in the wood preservation market. Russia and India are forecasted to have the fastest growth, growing at a CAGR of REDACTED% and REDACTED%, respectively.

The market is challenged by restraints such import duties on wood and wood products, and regulatory issues related to wood processing and wood preservation.

Report Scope:
This research report categorizes the wood preservation market by type.

Report Includes:
– 93 data tables
– An overview of the global market for wood preservation
– Analyses of global market trends, with data from 2013-2017, and projections of CAGRs through 2022
– Insight into the types of pressure treatment methods, including full-cell process, empty-cell process, low-pressure-treatment process, and double-vacuum process
– Coverage of nonpressure treatments methods, such as brushing, dip treatment, cold soaking, and thermal process
– Identification of major trends shaping the wood preservation market, such as environmentally-friendly wood preservation processes, alternative chemicals for wood preservation, color-treated wood technology for deck building, and micronized wood preservative technology
– Comprehensive profiles of the major companies in the market, including Metsa Group, Stella-Jones Inc., Universal Forest Products, Inc., UPM-Kymmene Corporation. and West Fraser Timber Co. LtdReport Scope:

This research report categorizes the wood preservation market by type.

Report Includes:
– 93 data tables
– An overview of the global market for wood preservation
– Analyses of global market trends, with data from 2013-2017, and projections of CAGRs through 2022
– Insight into the types of pressure treatment methods, including full-cell process, empty-cell process, low-pressure-treatment process, and double-vacuum process
– Coverage of nonpressure treatments methods, such as brushing, dip treatment, cold soaking, and thermal process
– Identification of major trends shaping the wood preservation market, such as environmentally-friendly wood preservation processes, alternative chemicals for wood preservation, color-treated wood technology for deck building, and micronized wood preservative technology
– Comprehensive profiles of the major companies in the market, including Metsa Group, Stella-Jones Inc., Universal Forest Products, Inc., UPM-Kymmene Corporation. and West Fraser Timber Co. LtdMETSA GROUP
STELLA-JONES INC.
UNIVERSAL FOREST PRODUCTS, INC.
UPM-KYMMENE CORPORATION
WEST FRASER TIMBER CO. LTD.
Table of Content: Key Points
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Chapter 2 Summary and Highlights
Chapter 3 Wood Preservation Market Characteristics
Chapter 4 Wood Preservation Market Size and Growth
Historic Market Growth
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3096323-wood-preservation-global-markets-to-2022

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Estrogen Receptor Beta – Disease Assessment and Therapeutics Analysis Forecasts to 2024

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Estrogen Receptor Beta – Pipeline Review, H1 2018”

Estrogen Receptor Beta

Overview                

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription..

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3079824-estrogen-receptor-beta-er-beta-or-nuclear-receptor

 

Major Key Players:

EndoCeutics Inc

Karo Pharma AB

Mithra Pharmaceuticals SA

Oasmia Pharmaceutical AB

Estrogen Receptor Beta Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Estrogen Receptor Beta    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Estrogen Receptor Beta   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 1, 5 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively

Estrogen Receptor Beta pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Estrogen Receptor Beta – Competitive Analysis

Key players are making innovative developments in Estrogen Receptor Beta industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Estrogen Receptor Beta.

The pipeline guide reviews pipeline therapeutics for Estrogen Receptor Beta by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Estrogen Receptor Beta therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Estrogen Receptor Beta therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Estrogen Receptor Beta.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3079824-estrogen-receptor-beta-er-beta-or-nuclear-receptor

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Estrogen Receptor – Disease Assessment and Therapeutics Analysis Forecasts to 2024

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) – Pipeline Review, H1 2018”

Estrogen Receptor

Overview                

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) – Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis.

It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3079823-estrogen-receptor-er-alpha-or-estradiol-receptor-or

 

Major Key Players:

Atossa Genetics Inc

Eagle Pharmaceuticals Inc

H3 Biomedicine Inc

Mithra Pharmaceuticals SA

Novartis AG

Nuevolution AB

Estrogen Receptor Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Estrogen Receptor    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Estrogen Receptor   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Estrogen Receptor (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 4 respectively.

Estrogen Receptor pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Estrogen Receptor – Competitive Analysis

Key players are making innovative developments in Estrogen Receptor industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Estrogen Receptor.

The pipeline guide reviews pipeline therapeutics for Estrogen Receptor by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Estrogen Receptor therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Estrogen Receptor therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Estrogen Receptor.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3079823-estrogen-receptor-er-alpha-or-estradiol-receptor-or

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire